BerGenBio completes recruitment into first stage of Phase II breast cancer trial with selective AXL inhibitor bemcentinib combined with KEYTRUDA®
Bergen, Norway, 19 February 2018 – BerGenBio ASA (OSE: BGBIO) announces that it has completed enrolment, ahead of schedule, of the planned 28 patients into the first stage of its Phase II clinical trial evaluating its investigational oral selective AXL inhibitor bemcentinib (BGB324) in combination with the Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as a potential new treatment regimen for advanced breast cancer.The Phase II trial (BGBC007) follows a two-stage design: it